Pay in 4 interest-free payments of $7.46 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
About the Company: AstraZeneca is a global #biopharma leader Strong presence in rare diseases and immunology About the Product (#Ultomiris): Complement inhibitor therapy Designed for #immune-mediated kidney disease Key Highlights: Breakthrough #Phase3 data Advancing #nephrology "Congratulations to AstraZeneca." Michel Demar,Aradhana Sarin,Philip Broadley,Euan Ashley,Birgit Conix,Ruud Dobber,David Fredrickson,Susan Galbraith Innovation is transforming kidney disease treatment. #Pharma #Nephrology #HealthcareInnovation FDA The National Institutes of Health Centers for Disease Control and Prevention ISO - International Organization for Standardization World Health Organization European Medicines Agency International Society of Nephrology American Society of Nephrology International Federation of Pharmaceutical Manufacturers & Associations || cGxP.wire || cGxP.Directory || cGxP.jobs || cGxP.Tech || To view or add a comment, sign in I've just been reading about Boehringer Ingelheim's exciting developments in the obesity treatment space
Peptides are a hot topic in the wellness space as more people self-medicate with them, aiming to get better skin, to help with longevity, to build muscle, and the list goes on
Impaired mitochondrial function in psychiatric disorders
Add 1.0 mL bacteriostatic water to a 10 mg combo vial (5 mg + 5 mg) 10 mg/mL total (5 mg/mL of each component)
US$ 29.00
US$ 26.79
US$ 23.59
